What happened
Mayo Clinic and Thermo Fisher Scientific have established Precure, a data analysis company focused on early disease detection and drug development using AI and multi-omics data from one million biospecimens.
The academic medical group Mayo Clinic has partnered with biotech supply company Thermo Fisher Scientific to launch a new data analysis entity named Precure. According to the organizations, the joint venture is designed to focus on early disease detection across a variety of conditions, with a specific emphasis on cancer, cardiometabolic conditions, auto-immune diseases, and neurological disorders.
Precure intends to build one of the largest biomedical datasets by utilizing data from one million biospecimens. The company plans to integrate genomic and proteomic information alongside patient data derived from clinical encounters. The organizations state that advanced AI and large-scale data analytics will serve as key technologies to identify patterns within these complex datasets.
Mayo Clinic will act as the majority owner of Precure, while Thermo Fisher holds a minority stake. Thermo Fisher contributes its expertise in mass spectrometry and associated products to support the venture. The biotech supplier has previously collaborated with Mayo Clinic since July of this year on the underlying research project, building on a working relationship that began in 2021 regarding advanced gene sequencing.
According to the founding partners, the initiative aims to help understand disease before symptoms appear. The stated objective is to accelerate discoveries leading to earlier diagnoses, more targeted treatments, and enhanced patient outcomes. The ongoing research project focuses on identifying early disease signals, while the new corporate entity aims to translate those findings into actionable solutions.
The enterprise intends to offer the infrastructure needed to generate population-scale molecular data. Mayo Clinic reports that the venture will impact hospital and clinic operations by translating discoveries into new diagnostics and therapeutics. The organizations claim the initiative creates opportunities to apply multi-omics data at a scale intended to improve human health.
Why it matters for AI for Pharmaceutical & Biotech
For pharmaceutical and biotech professionals, this venture creates a large-scale data asset combining one million biospecimens with multi-omics and patient records. If the initiative achieves its stated goals, the resulting population-scale molecular data and AI-driven pattern recognition could alter how early-stage targets are identified and how clinical datasets are leveraged for drug development pipelines.
What to do about it
- Monitor Precure's publications and data releases regarding multi-omics integration.
- Evaluate internal mass spectrometry workflows against Thermo Fisher's supported methodologies.
- Assess current AI pipelines for handling large-scale genomic and proteomic datasets.
Source: Mayo Clinic, Thermo Fisher Scientific launch new AI-supported diagnostics company – HealthExec (healthexec.com)
See Zekai first in Google
Paid remote work · AI for Pharmaceutical & Biotech
Paid remote AI jobs in AI for Pharmaceutical & Biotech
AI companies pay experts by the hour to test and improve AI. Remote and flexible. These roles are open now.
1,553 open roles · updated today
Get new roles like these by email
One short email each morning with new roles open in your country. Free. Unsubscribe any time.
The weekly AI briefing for your profession
One weekly email: the AI changes that actually affect your profession — tools, deals, and what to do about them.




